Semaglutide vs Tirzepatide: Comparing Side Effects and Tolerability

If you're choosing between semaglutide and tirzepatide, cost is one axis — covered in semaglutide vs tirzepatide: which is cheaper and more effective — but tolerability is the one you'll actually live with day to day. This is what the trial evidence says about how the two drugs compare on side effects, not just efficacy.

The one real head-to-head trial

Most of what gets compared between these two drugs comes from separate trials run years apart on different placebo groups, which makes side-by-side numbers approximate at best. SURPASS-2 is the exception — a genuine head-to-head randomized trial that put tirzepatide (at 5 mg, 10 mg, and 15 mg) directly against semaglutide (at 1 mg) in adults with type 2 diabetes¹. It's worth flagging the population and dose up front: this trial was run in people with type 2 diabetes, using semaglutide's diabetes dose (1 mg), not the higher 2.4 mg dose used for weight management in Wegovy. With that caveat, it's still the closest thing to an apples-to-apples tolerability comparison that exists.

What SURPASS-2 found on GI side effects

Across the three tirzepatide doses versus semaglutide, the trial reported¹:

- Nausea: 17%–22% (tirzepatide, by dose) vs. 18% (semaglutide) - Diarrhea: 13%–16% vs. 12% - Vomiting: 6%–10% vs. 8%

Read across the doses, the two drugs land in a similar range rather than one being dramatically more tolerable than the other — tirzepatide's lowest dose was roughly comparable to semaglutide, while its highest dose ran somewhat hotter on nausea and vomiting. Serious adverse events were reported in 5%–7% of tirzepatide patients across doses versus 3% of semaglutide patients¹, though the trial abstract doesn't break out how many of those were specifically GI-related versus other causes.

What the separate obesity trials suggest

Because SURPASS-2 was run in diabetes patients at diabetes doses, it's not a direct stand-in for how Wegovy and Zepbound compare in obesity treatment. For that, the closest available data is each drug's own FDA-labeled trial results — not a head-to-head, but run at the doses actually used for weight management. Wegovy's label reports 44% nausea and 24% vomiting at its 2.4 mg obesity dose; Zepbound's label reports nausea ranging from 25%–29% and vomiting from 8%–13% across its 5–15 mg dose range²³. See the full breakdown, including discontinuation rates, in GLP-1 side effects: what the STEP and SURMOUNT trials actually reported. Read cautiously: different trial populations, different placebo cohorts, and different follow-up lengths mean this isn't a clean comparison the way SURPASS-2 is — but it's the best available signal until a true head-to-head obesity trial is published.

Efficacy and tolerability moved together in SURPASS-2

It's worth noting what tirzepatide traded for its somewhat higher GI rates in SURPASS-2: it was superior to semaglutide on blood sugar control, with HbA1c reductions of 2.01–2.30 percentage points across its three doses versus 1.86 points for semaglutide¹. That pattern — a modestly higher side-effect rate at tirzepatide's top doses alongside a modestly stronger clinical result — echoes what shows up in the separate obesity trials too, where tirzepatide's higher weight-loss ceiling in SURMOUNT-1 comes with GI rates that run somewhat above Wegovy's at comparable relative dose intensity. Neither drug offers a free lunch: more effect and more side effects tend to move in the same direction as dose goes up, within each drug and to some extent between them.

The pattern that holds across both data sources

In both SURPASS-2 and the separate obesity-trial labeling, gastrointestinal side effects scale with dose for both drugs — the highest approved dose of either medication produces more nausea, vomiting, and diarrhea than the lowest. Neither drug is uniformly "gentler" across its full dose range; where you land depends heavily on which dose you and your prescriber settle on, which is exactly why the titration schedule matters as much as the drug choice itself.

Discontinuation isn't dramatically different

Despite differences in headline weight-loss numbers, discontinuation due to adverse events across both drugs' obesity trials clusters in the same rough range — mid-single digits to around 7% at the highest doses, versus roughly 3% on placebo²³. If tolerability is your deciding factor, that's a reason not to assume one drug is categorically easier to stay on than the other; individual response varies more than the population averages suggest.

Individual response is the variable the averages can't show you

Trial percentages describe a population, not a person. A patient who's highly sensitive to GI side effects might tolerate semaglutide better than tirzepatide despite the population averages looking similar, or vice versa — there's no reliable pre-treatment test to predict which drug a given individual will handle better. That's the practical argument for treating the first several weeks on either drug as a genuine trial period, with your prescriber, rather than locking into a choice based on trial averages alone and assuming your experience will match the group mean.

Making the call with your prescriber

Neither the efficacy edge nor the tolerability data alone should make this decision for you — a program's willingness to switch you between drugs, adjust your titration pace, or manage side effects as they come up matters more than the trial averages. We weigh that kind of medical flexibility in our Value Score methodology. Compare pricing for both drugs on our semaglutide and tirzepatide boards, and check how programs handle dose switches in our provider reviews.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.